MSCI USA IMI Biotech Advance Index

The MSCI USA IMI Biotech Advance Index aims to represent the performance of a set of companies across large, mid and small cap representation in the US market, that are associated with research, development, and commercialization of products for treating a broad range of diseases and disorders.
Get in touch
Document downloads
Index code
753365
Inception date
June 29, 2023
Div Yld (%)
0.71
P/E
4675.03
P/E Fwd
69.38
P/BV
6.09
Number of constituents
94
Index Market Cap
$2.22 T
Largest constituent Market Cap
$234.85 B
Smallest constituent Market Cap
$977.58 M
Average constituent Market Cap
$23.63 B
Median constituent Market Cap
$6.62 B
Data as of Sept. 30, 2024 

ESG metrics

Summary

MSCI USA IMI Biotech Advance Index

Implied Temperature Rise
> 1.5°C - < 2°C
81.91% coverage

MSCI ACWI IMI

Implied Temperature Rise
> 2.0°C - < 3.2°C
94.69% coverage
MSCI USA IMI Biotech Advance Index
Score
Coverage
ESG Score
6.25
100.00%
UN Global Compact Violations % (*)
0.00%
100.00%
Red Flag ESG Controversies % (*)
0.00%
100.00%
MSCI ACWI IMI
Score
Coverage
ESG Score
6.72
88.49%
UN Global Compact Violations % (*)
0.15%
97.03%
Red Flag ESG Controversies % (*)
0.16%
97.03%

(*) Additional ESG factor not mentioned in the regulation but provided for transparency purposes.

Data available as of Sept. 30, 2024. The information was updated as part of the regular monthly update cycle.

MSCI ESG and climate ratings, research and data are produced by MSCI ESG Research LLC, a subsidiary of MSCI Inc. MSCI ESG Indexes, Analytics, Real Assets, and Private Capital Solutions are products of MSCI Inc. that utilize information from MSCI ESG Research LLC. MSCI Indexes are administered by MSCI Limited and MSCI Deutschland GmbH.

Want to learn more about MSCI indexes?
Get in touch.

Contact us